Skip to main content
CMS proposes national coverage policy for CAR T-cell therapies

Medicare would cover chimeric antigen receptor T-cell therapies approved by the FDA under a proposal from the CMS, which would include Kymriah, or tisagenlecleucel, and Yescarta, or axicabtagene ciloleucel. The proposed National Coverage Determination would cover CAR T-cell therapies offered through clinical trials or CMS-approved registries, according to the CMS.

Full Story: